Dan Burgess

Venture Partner

Dan joined SV Health Investors as a Venture Partner in 2014.

Prior experience
Prior to joining SV, Dan was founder, President and CEO of Rempex Pharmaceuticals, Inc. (SVLS Fund V), an antibiotic company that was sold to the Medicines Company two years after its founding in a transaction valued at up to $475 million. Previously Dan was President and CEO of Mpex Pharmaceuticals, Inc. (SVLS Fund IV), a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials; the drug was acquired by Aptalis, Inc. in 2011. Dan has also held senior executive positions at a number of other biotechnology companies. He served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion.


Academic credentials
AB, Economics, Stanford University; MBA, Harvard Business School.

Outside of SV
Dan holds the following external Board seats: Nabriva Therapeutics (Chairman, NASDAQ:NBRV), Atox Bio (Chairman), Cidara Therapeutics (NASDAQ: CDTX) and Arbutus Biopharma (NASDAQ: ABUS). He is also Chairman of Biocom, the life science industry association of California that represents more than 800 member companies. In his spare time, Dan is an avid golfer and also dabbles in the music industry.

Venture Partners


Sector Administrator
Maura Williams


Current Portfolio

Past Portfolio

Mpex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc.